स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lohmann animal health gmbh -

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zoetis belgium sa -

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zoetis belgium sa -

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intervet international -

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zoetis belgium rue laid burniat 1 1348 louvain -

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

era consulting gmbh - pegfilgrastim - nevtropenija - immunostimulants, , colony stimulating factors - skrajšanje trajanja nevtropenija in pojavnost vročinskih nevtropenija pri odraslih bolnikih, zdravljenih s citotoksično kemoterapijo za malignosti (razen kronično mieloično levkemijo in mielodisplastični sindrom).

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imunski sera in imunoglobulini, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - bolezni migrene - analgetiki - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

instituto grifols s.a. - Človekove normalno imunoglobulina - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imunski sera in imunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - zdravilo agenerase, v kombinaciji z drugimi protiretrovirusnimi zdravili, je indicirano za zdravljenje zaviralcev proteaze (pi), ki so se doživeli odrasli in otroci, okuženi s hiv-1, in njihovi otroci, starejši od 4 let. kapsule agenerase je običajno treba dajati z majhnim odmerkom ritonavirja kot farmakokinetičnega povečevalnika amprenavirja (glejte poglavja 4. 2 in 4. izbira amprenavirja mora temeljiti na testiranju odpornosti na posamezne virusne odmerke in zgodovini zdravljenja bolnikov (glejte poglavje 5). koristi agenerase razširila z ritonavir ni bila dokazana v pi ladjo bolnikih (glejte poglavje 5.